RT Journal Article
SR Electronic
T1 Independent information from PET, CSF and plasma biomarkers of tau pathology in Alzheimer’s disease
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.04.19.440402
DO 10.1101/2021.04.19.440402
A1 Rik Ossenkoppele
A1 Juhan Reimand
A1 Ruben Smith
A1 Antoine Leuzy
A1 Olof Strandberg
A1 Sebastian Palmqvist
A1 Erik Stomrud
A1 Henrik Zetterberg
A1 the Alzheimer’s Disease Neuroimaging Initiative
A1 Philip Scheltens
A1 Jeffrey L. Dage
A1 Femke Bouwman
A1 Kaj Blennow
A1 Niklas Mattsson-Carlgren
A1 Shorena Janelidze
A1 Oskar Hansson
YR 2021
UL http://biorxiv.org/content/early/2021/04/19/2021.04.19.440402.abstract
AB PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzheimer’s disease (AD) related demographic, cognitive, genetic and neuroimaging markers. We examined 771 participants with normal cognition, mild cognitive impairment or dementia from BioFINDER-2 (n=400) and ADNI (n=371). All had tau-PET ([18F]RO948 in BioFINDER-2, [18F]flortaucipir in ADNI) and CSF p-tau181 biomarkers available. Plasma p-tau181 and plasma/CSF p-tau217 were available in BioFINDER-2 only. Concordance between PET, CSF and plasma tau biomarkers ranged between 66% and 95%. Across the whole group, ridge regression models showed that increased CSF and plasma p-tau181 and p-tau217 levels were independently of tau PET associated with higher age, and APOEε4-carriership and Aβ-positivity, while increased tau-PET signal in the temporal cortex was associated with worse cognitive performance and reduced cortical thickness. We conclude that biofluid and neuroimaging markers of tau pathology convey partly independent information, with CSF and plasma p-tau181 and p-tau217 levels being more tightly linked with early markers of AD (especially Aβ pathology), while tau-PET shows the strongest associations with cognitive and neurodegenerative markers of disease progression.Competing Interest StatementThe authors have declared no competing interest.